A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
Public ClinicalTrials.gov record NCT00650611. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 27-Week Open-Label Trial To Characterize The Safety And Tolerability Of Orally Administered Ziprasidone In Children And Adolescent Subjects With Bipolar I Disorder (Manic Or Mixed), Schizophrenia Or Schizoaffective Disorder
Study identification
- NCT ID
- NCT00650611
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Enrollment
- 63 participants
Conditions and interventions
Interventions
- Ziprasidone Drug
Drug
Eligibility (public fields only)
- Age range
- 10 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2003
- Primary completion
- Not listed
- Completion
- Feb 28, 2005
- Last update posted
- Feb 20, 2021
2003 – 2005
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | San Diego | California | 92111 | — |
| Pfizer Investigational Site | Altamonte Springs | Florida | 32701 | — |
| Pfizer Investigational Site | Libertyville | Illinois | 60048 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40509 | — |
| Pfizer Investigational Site | Belmont | Massachusetts | 02478 | — |
| Pfizer Investigational Site | Brighton | Massachusetts | 02135 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89103 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89117 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89128 | — |
| Pfizer Investigational Site | Turnersville | New Jersey | 08012 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45224 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45229 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267-0559 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44106 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19104-3309 | — |
| Pfizer Investigational Site | Kirkland | Washington | 98033 | — |
| Pfizer Investigational Site | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00650611, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2021 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00650611 live on ClinicalTrials.gov.